Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M7,072Revenue (TTM) $M384Net Margin (%)-27.2Altman Z-Score21.3
Enterprise Value $M6,463EPS (TTM) $-0.8Operating Margin %-27.6Piotroski F-Score4
P/E(ttm)--Beneish M-Score-1.3Pre-tax Margin (%)-27.2Higher ROA y-yN
Price/Book10.610-y EBITDA Growth Rate %-3.7Quick Ratio5.3Cash flow > EarningsN
Price/Sales17.65-y EBITDA Growth Rate %-3.6Current Ratio5.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-13.2Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-17.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M141ROIC % (ttm)-879.5Gross Margin Increase y-yY

Gurus Latest Trades with SGEN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
SGENGeorge Soros 2016-06-30 Buy 0.02%$32.95 - $43.78
$ 50.3332%New holding14,700
SGENJoel Greenblatt 2016-06-30 Buy 0.01%$32.95 - $43.78
$ 50.3332%New holding30,082
SGENVanguard Health Care Fund 2015-12-31 Sold Out -0.01%$37.16 - $45.52
$ 50.3321%Sold Out0
SGENVanguard Health Care Fund 2015-06-30 Buy 0.02%$34.03 - $49.63
$ 50.3322%New holding170,125
SGENFirst Eagle Investment 2010-03-31 Sold Out -0.01%$9.34 - $12.59
$ 50.33364%Sold Out0
SGENFirst Eagle Investment 2009-12-31 Buy 0.01%$8.74 - $13.16
$ 50.33419%New holding67,373
SGENBill Gates 2009-09-30 Sold Out -0.39%$8.75 - $14.8
$ 50.33331%Sold Out0
SGENFirst Eagle Investment 2009-06-30 Sold Out -0.01%$8.18 - $10.34
$ 50.33452%Sold Out0
SGENFirst Eagle Investment 2009-03-31 Add$7.23 - $10.36
$ 50.33435%Add 40.00%70,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SGEN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!

SGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SIEGALL CLAY BPresident and CEO 2016-10-06Sell14,465$54.41-7.5view
DRACHMAN JONATHAN GCMO & EVP, R & D 2016-09-22Sell2,249$56.75-11.31view
DOBMEIER ERICCOO 2016-09-14Sell22,918$54.04-6.87view
BAKER FELIXDirector, 10% Owner 2016-09-13Buy447,311$50.71-0.75view
BAKER FELIXDirector, 10% Owner 2016-09-08Buy414,016$48.433.92view
SIEGALL CLAY BPresident and CEO 2016-09-08Sell31,269$50.080.5view
SIEGALL CLAY BPresident and CEO 2016-09-06Sell11,653$45.410.86view
Cline Darren SEVP, Commercial 2016-09-06Sell5,397$46.019.39view
DOBMEIER ERICCOO 2016-08-23Sell12,589$484.85view
Cline Darren SEVP, Commercial 2016-08-22Sell1,774$46.598.03view

Quarterly/Annual Reports about SGEN:

News about SGEN:

Articles On GuruFocus.com
Insiders Roundup: Theravance Biopharma, Western Gas, Upland Software Mar 18 2016 
Top Insider Trades of the Past Week Feb 19 2016 
Insiders Are Buying Barnes & Noble Sep 18 2015 
Vanguard Health Care Fund Buys Two New Stakes in Second Quarter Aug 06 2015 
Insiders keep on buying Macerich Co and Seattle Genetics May 22 2015 
Insiders new buys : ZU, SGEN, MAC, SHLD, TBRA May 12 2015 
Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 

More From Other Websites
Drug Stock Q3 Earnings Roster for Oct 27: AMGN, BMY & More Oct 26 2016
Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma Treatment Paradigm through... Oct 20 2016
Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma Treatment Paradigm through... Oct 20 2016
Seattle Genetics creates new C-suite role as it seeks profitability Oct 17 2016
Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : October... Oct 17 2016
Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics Oct 13 2016
SEATTLE GENETICS INC /WA Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 12 2016
Seattle Genetics and Agensys, an Affiliate of Astellas, Highlight Promising Enfortumab Vedotin... Oct 07 2016
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2016 Financial... Oct 06 2016
Seattle Genetics Announces Executive Promotions and Leadership Appointment Oct 04 2016
[$$] Two Cancer Biotechs See Bullish Insider Buying Sep 27 2016
Blue Jay Capital Betting On Big Returns From These Healthcare Stocks Sep 22 2016
Seattle Genetics Initiates Phase 1 Trial of SGN-CD123A for Patients with Relapsed or Refractory... Sep 19 2016
Massive Buffett Trade Again Highlights Insider Buying: Phillips 66, Seattle Genetics, Penske... Sep 18 2016
Seattle Genetics Inc (SGEN): Baker Bros. Advisors Raises Stake Sep 16 2016
Aerie Pharmaceuticals Skyrockets On Eye Drug News Sep 15 2016
Seattle Genetics upgraded by Goldman Sep 15 2016
Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar Sep 14 2016
Watch Oracle, Casinos, Biotechs For Thursday's Investing Action Plan Sep 14 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)